# Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

> **NCT04782687** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **US Oncology Research** · enrollment: 73 (actual)

## Conditions studied

- Multiple Myeloma
- Myeloma Multiple
- Kahler Disease
- Myeloma, Plasma Cell
- Myeloma-Multiple
- Myelomatosis
- Plasma Cell Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Dexamethasone Oral
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04782687
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-10
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04782687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04782687, "Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04782687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*